Friday 19 February 2016

Primary immunodeficiency disease (PIDD) comprises group of rare disorders, mostly genetic in nature, wherein a part of the immune system is missing or does not function correctly. The symptoms include a markedly increased vulnerability to serious illness and infection, organ damage and the immune system also attacking the body’s own tissues and cells. Primary Immunodeficiency is largely treated with therapies derived from human plasma, and in the most severe forms, replacement of stem cells. The report on global primary immunodeficiency diseases market by treatment has been studied and assessed for four prominent categories: Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem cells and gene therapy and others. The market for others provide a cumulative estimation for vaccines and nutritional supplement.

Browse Full Report With TOC:- http://www.transparencymarketresearch.com/primary-immunodeficiency-disease-market.html

Immunoglobulin (Ig) has been used to treat hypogammaglobulinaemia for more than two decades or more. Recently, it has also been used to treat diseases such as combined immunodeficiency and partial antibody deficiency. Ig are as a replacement therapy are usually administered via two prominent modes i.e. intravenous and subcutaneous which has well demonstrated their efficacy and safety in primary immunodeficiency (PIDD) treatment. A recent survey published by the Medical Insights Groups in 2014 illustrated that 54% of home-based Ig are delivered through SC, whereas only 46% are considered for IV in the U.S. Demand for SC is growing rapidly especially among school going children as it can be delivered in home settings with a one hour infusion, whereas venous access requires three to four hour infusion for IVIG.

Long-term prophylactic antibiotics are being widely implemented as primary or adjunctive therapy for PIDD treatment. This practice has transformed clinical outcomes in the setting of chronic granulomatous disease, complement deficiencies, Wiskott-Aldrich syndrome, hyper IgE syndrome. Patients with PIDD are often prescribed longer and stronger courses of antibiotics than usual. This could mean courses of 14 days or sometimes longer. The reason for this is to prevent relapse or recurrence of infection. Some of the commonly used antibiotics in PIDD treatment include penicillin, cephalosporins, macrolides, fluoroquinolones, sulfonamides, tetracyclines, and aminoglycosides.

Hematopoietic stem cell treatment (HSCT) successfully cures a wide range of primary immunodeficiency disorders. Advances in medical science has led to an improved survival rate and better quality of life, especially with respect to orphan diseases. HSCT owing to its better outcomes is now increasingly practiced for treating non-SCID based patients suffering from diseases such as Wiskott-Aldrich syndrome, Omenn syndrome, CD40 ligand deficiency and others. Gene therapy has been used to treat patients with SCID due to adenosine deaminase (ADA) deficiency, X-linked severe combined immunodeficiency, chronic granulomatous disease, and Wiskott-Aldrich syndrome. Various laboratories across the world are working at modifications of the viral vectors in order to improve their safety. Stem cells and gene therapy market is expected to be the fastest growing segment during the forecast tenure owing to increasing number of clinical trial and research studies and significant reduction in mortality and morbidity in past few years.

Lack of adequate nutrition can also lead to many illnesses including infections for which the individual with primary immunodeficiency disease is already at risk. Vitamin supplements include vitamins A, C, and E, which are all valuable parts of the body's defense system aid in increasing the production of healthy white blood cells and to fight infection.

The report offers a detailed description behind this high growth and outlines a possible growth trajectory for other segments of PIDD market such as by diseases, by test and by geography. The market study also profiled some of the leading companies operating in primary immunodeficiency diseases market across the globe. These encompasses Baxter International, Inc., Biotest AG, CSL Behring LLC, Bio Products Laboratory Ltd., Kedrion S.p.A., LFB S.A., Octapharma AG and Grifols S.A.

The global primary immunodeficiency diseases market is segmented into the following categories:
Global Primary Immunodeficiency Diseases Market, by Disease

Antibody Deficiency
Agammaglobulinaemia ((X-Linked and Autosomal Recessive)
Common Variable Immune Deficiency
Selective IgA Deficiency
IgG Subclass Deficiency
Others

Cellular Immunodeficiency
Ataxia Telangiectasia
Hyper IgM Syndromes
Wiskott-Aldrich Syndrome
DiGeorge Syndrome
Others

Innate Immune Disorders
Complement Deficiencies
Hyper IgE Syndrome
Others

Global Primary Immunodeficiency Diseases Market, by Test
Blood Test
Prenatal Testing

Global Primary Immunodeficiency Diseases Market, by Treatment
Immunoglobulin Replacement Therapy
Antibiotic Therapy
Stem cell and Gene Therapy
Others

Request For Sample Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=3137

About Us:-

Transparency Market Research (TMR) is a next-generation provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact Us:-

Mr.Sudip.S
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
Email: sales@transparencymarketresearch.com
Several couples in recent years have realized the potential of umbilical cord blood, making cord blood banking a priority. By choosing to bank cord blood, parents not only open up the possibility of saving their child’s life if it is threatened by a disease, but also the life of a family member, relative, or a stranger. Cord blood refers to blood extracted from the umbilical cord and the placenta after the baby is born. The reason cord blood is stored in medical facilities across the world is that the blood cells it contains have the ability to renew themselves.

Browse Full Report: http://www.transparencymarketresearch.com/latam-cord-blood-banking-services-market.html

Rising Awareness about Cord Blood Banking Gives an Impetus to Blood Banking Services

As more and more parents are realizing the importance of saving cord blood, banking units that offer services such as collection and preservation are booming, especially in Latin American countries. The top players in the Latin America cord blood baking services market are Banco de Cordon Umbilical (BCU), Redcord S.A., America Cell Biobank, Inc., and CrioCenter. These banks are either private cord blood banking services or public cord blood banking services. Most of them are operating in countries such as Brazil, Colombia, Argentina, and Mexico. 

Growing Stem Cell Research Promotes Cord Blood Banking

Umbilical cord blood has a huge potential to be the source of progenitor cells that are usually used for the reconstitution of organs, tissues, and other functional areas. Today, cord blood transplantation is being used for treating a variety of diseases such a sarcoma, leukemia, lymphoma, and several other immune conditions and metabolic disorders. In the last twenty years, the stem cell therapeutics industry has also experienced a surge due to increasing investment and growing research and development.

Private Cord Blood Banking Services Toughen the Competition in the Market

The rise in technological and infrastructural development in Latin American countries has encouraged research into stem cell therapy, which has given cord blood banking a positive momentum. Most cord blood banking services in Latin America are being funded by governments. However, as private players are slowly making their way into the Latin American market, they are likely to make the scenario highly competitive for the existing players.

Browse Press Release: http://www.transparencymarketresearch.com/pressrelease/latam-cord-blood-banking-services-market.htm

In the coming years, countries in Latin America are expected to make a serious effort at reducing the limitation of public and private cord blood banking by executing a hybrid model. This model will entail the storage of cord blood for a dual purpose. One part of it will be used for the child or for the donor family, while the second portion will be used as a public donation. With the myriad possibilities that cord blood banking services offer and the remarkable progress in stem cell research, saving this blood could prove to be lifeline for future generations.

Download PDF Brochure: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=8413

About Us:-

Transparency Market Research (TMR) is a next-generation provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact Us:-
Mr.Sudip.S
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
Email: sales@transparencymarketresearch.com